Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
STE · against 99 other Healthcare companies of similar size
Ranked #40 of 100 · scores higher than 60% of peers
Bars: peers in each 10-point band of the valuation score20 peers with a valuation score of 60–69, including STE · Click a bar to see the companies
Mainly thanks to its free cash flow yield, earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | STE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 98 reported | 3.5% | 3.2% | 58% | 30% | |
| EBITDA yieldHigher is better · 100 reported | 6.8% | 5.8% | 67% | 50% | |
| Free cash flow yieldHigher is better · 62 reported | 4.1% | 3.9% | 52% | 20% | |
| Book yieldHigher is better · 94 reported | 31.9% | 21.6% | 66% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 2 | 21.5B USD | 95 | 60 | |
| 3 | 11.6B USD | 94 | 58 | |
| 3 | 68.0B BRL (≈$12.2B) | 94 | 67 | |
| 5 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 36 | 133.4B BRL (≈$24.0B) | 67 | 49 | |
| 38 | 83.0B CNY (≈$11.6B) | 66 | 62 | |
| 38 | 27.3B USD | 66 | 55 | |
| 40 | 177.2B HKD (≈$22.7B) | 65 | 73 | |
| 40 | 22.6B USD | 65 | 59 | |
| 42 | 225.2B CNY (≈$31.5B) | 64 | 63 | |
| 42 | 193.6B HKD (≈$24.8B) | 64 | 78 | |
| 42 | 16.8B USD | 64 | 75 | |
| 45 | 111.7B DKK (≈$16.8B) | 63 | 53 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score